Neoleukin Therapeutics (NASDAQ:NLTX)’s share price traded down 0.7% during trading on Thursday . The company traded as low as $2.91 and last traded at $2.93, 1,200 shares traded hands during mid-day trading. A decline of 97% from the average session volume of 39,169 shares. The stock had previously closed at $2.95.
Separately, ValuEngine downgraded Neoleukin Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, September 12th.
The firm has a fifty day moving average price of $2.96.
Neoleukin Therapeutics Company Profile (NASDAQ:NLTX)
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy.
Further Reading: What are the benefits of a balanced fund?
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.